{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:44:44Z","timestamp":1789767884877,"version":"4.0.1"},"reference-count":73,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Difficult-to-treat systemic lupus erythematosus (D2T-SLE) remains a major unmet challenge in contemporary lupus care, yet it continues to be defined predominantly by clinical non-response rather than underlying biology. Current biomarkers largely quantify inflammatory burden, immune complex activity, or organ damage and do not reliably capture persistent activation of pathogenic pathways under therapy. Emerging multi-omics, single-cell, and longitudinal studies suggest that, in a subset of patients, apparent treatment failure may reflect incomplete attenuation of dominant immune circuits rather than uniformly elevated inflammation. We propose molecular refractoriness in systemic lupus erythematosus (SLE) as sustained, pathway-level immune activity despite apparently adequate, mechanism-directed therapy. We outline the major immune programs implicated in this process\u2014including interferon-enriched, B-cell\/plasmablast-associated, neutrophil extracellular trap (NET)-related, cytotoxic T-cell, and cytokine-associated states\u2014and discuss their relevance for biomarker development and precision trial design. Importantly, we emphasize that interferon gene signatures (IGS) should be interpreted as context-dependent and non-specific markers of interferon responsiveness, reflecting combined activity of type I, II, and III interferons, and functioning primarily as predictive rather than mechanistic biomarkers. We further highlight critical limitations of a purely endotype-based model, including the need to distinguish true molecular refractoriness from damage-dominant and pseudo-refractory states, as well as the emerging role of immune-reset strategies such as cluster of differentiation 19 (CD19)-directed chimeric antigen receptor T-cell (CAR-T) therapy, which may overcome refractoriness independently of specific pathway dominance. These observations suggest that difficult-to-treat SLE encompasses biologically heterogeneous states that may not be fully captured by pathway-resolved stratification alone. Reframing D2T-SLE as a biologically heterogeneous state of incomplete immune attenuation may help bridge the gap between clinical treatment failure and mechanism-informed precision medicine in systemic lupus erythematosus.<\/jats:p>","DOI":"10.3390\/ijms27094026","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:20:25Z","timestamp":1777551625000},"page":"4026","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Redefining Difficult-to-Treat Systemic Lupus Erythematosus: Biomarkers of Molecular Refractoriness Beyond Clinical Failure"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6117-0853","authenticated-orcid":false,"given":"Agata","family":"Matusiewicz","sequence":"first","affiliation":[{"name":"Department of Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, 02-637 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"Pa\u015b","sequence":"additional","affiliation":[{"name":"Department of Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, 02-637 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2895-4178","authenticated-orcid":false,"given":"Sylwia","family":"Wiktorzak","sequence":"additional","affiliation":[{"name":"Department of Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, 02-637 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3028-1061","authenticated-orcid":false,"given":"Marzena","family":"Olesi\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, 02-637 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1136\/annrheumdis-2017-211663","article-title":"Survival in Adults and Children with Systemic Lupus Erythematosus: A Systematic Review and Bayesian Meta-Analysis of Studies from 1950 to 2016","volume":"76","author":"Tektonidou","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/ard-2023-224919","article-title":"Pragmatic Targets for Moderate\/Severe SLE and Their Implications for Clinical Care and Trial Design: Sustained DORIS or LLDAS for at Least 6 Months Is Sufficient While Their Attainment for at Least 24 Months Ensures High Specificity for Damage-Free Progression","volume":"83","author":"Pitsigavdaki","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.berh.2017.09.009","article-title":"Treat to Target, Remission and Low Disease Activity in SLE","volume":"31","author":"Morand","year":"2017","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"v19","DOI":"10.1093\/rheumatology\/keaa420","article-title":"Treatment Targets in SLE: Remission and Low Disease Activity State","volume":"59","author":"Golder","year":"2020","journal-title":"Rheumatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e000538","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS Definition of Remission in SLE: Final Recommendations from an International Task Force","volume":"8","author":"Bertsias","year":"2021","journal-title":"Lupus Sci. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/S2665-9913(19)30037-2","article-title":"Lupus Low Disease Activity State as a Treatment Endpoint for Systemic Lupus Erythematosus: A Prospective Validation Study","volume":"1","author":"Golder","year":"2019","journal-title":"Lancet Rheumatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/rheumatology\/keae120","article-title":"Lupus Low Disease Activity State and Organ Damage in Relation to Quality of Life in Systemic Lupus Erythematosus: A Cohort Study with up to 11 Years of Follow-Up","volume":"64","author":"Parodis","year":"2025","journal-title":"Rheumatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/art.40571","article-title":"Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort","volume":"70","author":"Petri","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Sammaritano, L.R., Askanase, A., Bermas, B.L., Dall, M., Duarte-Garc\u00eda, A., Hiraki, L.T., Son, M.B.F., Werth, V.P., Aranow, C., and Barnado, A. (2025). 2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus. Arthritis Care Res., Epub ahead of printing.","DOI":"10.1002\/acr.25690"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 Update of the EULAR Recommendations for the Management of Systemic Lupus Erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41584-021-00739-3","article-title":"Treat-to-Target in Systemic Lupus Erythematosus: Advancing towards Its Implementation","volume":"18","author":"Voskuyl","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Gao, D., Ji, L., Zhang, X., Hao, Y., Xie, W., Fan, Y., and Zhang, Z. (2025). Transitioning from Lupus Low Disease Activity State to Remission in Systemic Lupus Erythematosus: Real-World Evidence. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1546306"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/rheumatology\/kead166","article-title":"Which Extra-Renal Flare Is \u201cdifficult to Treat\u201d in Systemic Lupus Erythematosus? A One-Year Longitudinal Study Comparing Traditional and Machine Learning Approaches","volume":"63","author":"Maffi","year":"2024","journal-title":"Rheumatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e584","DOI":"10.1016\/S2665-9913(23)00209-6","article-title":"Impact of Low Disease Activity, Remission, and Complete Remission on Flares Following Tapering of Corticosteroids and Immunosuppressive Therapy in Patients with Systemic Lupus Erythematous: A Multinational Cohort Study","volume":"5","author":"Cho","year":"2023","journal-title":"Lancet Rheumatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1016\/S2665-9913(24)00340-0","article-title":"The Concept of Difficult-to-Treat Disease in Rheumatology: Where Next?","volume":"7","author":"Nagy","year":"2025","journal-title":"Lancet Rheumatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"101896","DOI":"10.1016\/j.berh.2023.101896","article-title":"Assessment of Disease Activity and Damage in SLE: Are We There Yet?","volume":"37","author":"Cruciani","year":"2023","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_17","first-page":"1338","article-title":"Histologic versus Clinical Remission in Proliferative Lupus Nephritis","volume":"32","author":"Malvar","year":"2017","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc.\u2014Eur. Ren. Assoc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1136\/annrheumdis-2013-205171","article-title":"Factors Associated with Damage Accrual in Patients with Systemic Lupus Erythematosus: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort","volume":"74","author":"Bruce","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1093\/rheumatology\/keu148","article-title":"Glucocorticoids and Irreversible Damage in Patients with Systemic Lupus Erythematosus","volume":"53","author":"Ugarte","year":"2014","journal-title":"Rheumatology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e000157","DOI":"10.1136\/lupus-2016-000157","article-title":"Independent Association of Glucocorticoids with Damage Accrual in SLE","volume":"3","author":"Apostolopoulos","year":"2016","journal-title":"Lupus Sci. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40265-022-01824-x","article-title":"Refractory Systemic Lupus Erythematosus: Identification and Pharmacological Management","volume":"83","author":"Roccatello","year":"2023","journal-title":"Drugs"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13075-019-1878-y","article-title":"High Levels of Circulating Interferons Type I, Type II and Type III Associate with Distinct Clinical Features of Active Systemic Lupus Erythematosus","volume":"21","author":"Oke","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e000170","DOI":"10.1136\/lupus-2016-000170","article-title":"Interferon (IFN)-\u03bb Is a Potential Mediator in Lupus Nephritis","volume":"3","author":"Zickert","year":"2016","journal-title":"Lupus Sci. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e000063","DOI":"10.1136\/lupus-2014-000063","article-title":"BAFF (B Cell Activating Factor) Transcript Level in Peripheral Blood of Patients with SLE Is Associated with Same-Day Disease Activity as Well as Global Activity over the next Year","volume":"2","author":"Zollars","year":"2015","journal-title":"Lupus Sci. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/art.39809","article-title":"Post Hoc Analysis of the Phase II\/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL","volume":"69","author":"Gordon","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Zickert, A., Amoudruz, P., Sundstr\u00f6m, Y., R\u00f6nnelid, J., Malmstr\u00f6m, V., and Gunnarsson, I. (2015). IL-17 and IL-23 in Lupus Nephritis\u2014Association to Histopathology and Response to Treatment. BMC Immunol., 16.","DOI":"10.1186\/s12865-015-0070-7"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41581-023-00797-8","article-title":"Vascular Damage in Systemic Lupus Erythematosus","volume":"20","author":"Ambler","year":"2024","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2665-9913(22)00332-0","article-title":"Identification of Biomarkers to Stratify Response to B-Cell-Targeted Therapies in Systemic Lupus Erythematosus: An Exploratory Analysis of a Randomised Controlled Trial","volume":"5","author":"Shipa","year":"2023","journal-title":"Lancet Rheumatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"v12","DOI":"10.1093\/rheumatology\/keaa484","article-title":"New Biomarkers in SLE: From Bench to Bedside","volume":"59","author":"Capecchi","year":"2020","journal-title":"Rheumatology"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Idborg, H., and Oke, V. (2021). Cytokines as Biomarkers in Systemic Lupus Erythematosus: Value for Diagnosis and Drug Therapy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111327"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1159\/000517852","article-title":"Prognostic and Diagnostic Values of Novel Serum and Urine Biomarkers in Lupus Nephritis: A Systematic Review","volume":"52","author":"Radin","year":"2021","journal-title":"Am. J. Nephrol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/s41590-020-0743-0","article-title":"Mapping Systemic Lupus Erythematosus Heterogeneity at the Single-Cell Level","volume":"21","author":"Hong","year":"2020","journal-title":"Nat. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4049\/jimmunol.1100450","article-title":"Netting Neutrophils Induce Endothelial Damage, Infiltrate Tissues, and Expose Immunostimulatory Molecules in Systemic Lupus Erythematosus","volume":"187","author":"Villanueva","year":"2011","journal-title":"J. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/ard.2008.094508","article-title":"Are Laboratory Tests Useful for Monitoring the Activity of Lupus Nephritis? A 6-Year Prospective Study in a Cohort of 228 Patients with Lupus Nephritis","volume":"68","author":"Moroni","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/0961203310379871","article-title":"Simultaneous Detection of Anti-C1q and Anti-Double Stranded DNA Autoantibodies in Lupus Nephritis: Predictive Value for Renal Flares","volume":"20","author":"Matrat","year":"2011","journal-title":"Lupus"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/1529-0131(199901)42:1<187::AID-ANR24>3.0.CO;2-U","article-title":"Lack of Occurrence of Severe Lupus Nephritis among Anti-C1q Autoantibody-Negative Patients","volume":"42","author":"Trendelenburg","year":"1999","journal-title":"Arthritis Rheum."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Palazzo, L., Lindblom, J., Mohan, C., and Parodis, I. (2022). Current Insights on Biomarkers in Lupus Nephritis: A Systematic Review of the Literature. J. Clin. Med., 11.","DOI":"10.3390\/jcm11195759"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1186\/ar2816","article-title":"Urinary TWEAK as a Biomarker of Lupus Nephritis: A Multicenter Cohort Study","volume":"11","author":"Schwartz","year":"2009","journal-title":"Arthritis Res. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e000298","DOI":"10.1136\/lupus-2018-000298","article-title":"Urine TWEAK Level as a Biomarker for Early Response to Treatment in Active Lupus Nephritis: A Prospective Multicentre Study","volume":"6","author":"Suttichet","year":"2019","journal-title":"Lupus Sci. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of Anifrolumab in Active Systemic Lupus Erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"eabf1970","DOI":"10.1126\/science.abf1970","article-title":"Single-Cell RNA-Seq Reveals Cell Type-Specific Molecular and Genetic Associations to Lupus","volume":"376","author":"Perez","year":"2022","journal-title":"Science"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.38628","article-title":"Modular Transcriptional Repertoire Analyses of Adults with Systemic Lupus Erythematosus Reveal Distinct Type I and Type II Interferon Signatures","volume":"66","author":"Chiche","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/s41590-019-0398-x","article-title":"The Immune Cell Landscape in Kidneys of Patients with Lupus Nephritis","volume":"20","author":"Arazi","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ard.2025.12.002","article-title":"Treatment Nonresponders in Lupus Nephritis Characteristically Exhibit Persistent Type I Interferon Signalling in Monocytes: A Longitudinal Single-Cell Transcriptomic Analysis","volume":"85","author":"Kim","year":"2026","journal-title":"Ann. Rheum. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.kint.2022.05.033","article-title":"Molecular Profiling of Kidney Compartments from Serial Biopsies Differentiate Treatment Responders from Non-Responders in Lupus Nephritis","volume":"102","author":"Parikh","year":"2022","journal-title":"Kidney Int."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/ni.3175","article-title":"Diversity, Cellular Origin and Autoreactivity of Antibody-Secreting Cell Population Expansions in Acute Systemic Lupus Erythematosus","volume":"16","author":"Tipton","year":"2015","journal-title":"Nat. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"101569","DOI":"10.1016\/j.xcrm.2024.101569","article-title":"Uncoupling Interferons and the Interferon Signature Explains Clinical and Transcriptional Subsets in SLE","volume":"5","author":"Goldman","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"103525","DOI":"10.1016\/j.jaut.2026.103525","article-title":"Molecular Stratification and Transcriptome-Guided Therapeutics in Systemic Lupus Erythematosus with Insufficient Treatment Response","volume":"159","author":"Beretta","year":"2026","journal-title":"J. Autoimmun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and Safety of Belimumab in Patients with Active Systemic Lupus Erythematosus: A Randomised, Placebo-Controlled, Phase 3 Trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Saegusa, K., Tsuchida, Y., Komai, T., Tsuchiya, H., and Fujio, K. (2025). Advances in Targeted Therapy for Systemic Lupus Erythematosus: Current Treatments and Novel Approaches. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26030929"},{"key":"ref_52","unstructured":"FDA-NIH Biomarker Working Group (2016). BEST (Biomarkers, EndpointS, and Other Tools) Resource."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e001090","DOI":"10.1136\/lupus-2023-001090","article-title":"Interpreting Hydroxychloroquine Blood Levels for Medication Non-Adherence: A Pharmacokinetic Study","volume":"11","author":"Balevic","year":"2024","journal-title":"Lupus Sci. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of Action of Hydroxychloroquine and Chloroquine: Implications for Rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T Cell Therapy for Refractory Systemic Lupus Erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell Therapy in Autoimmune Disease\u2014A Case Series with Follow-Up","volume":"390","author":"Taubmann","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and Challenges in CAR T Cell Therapy in Autoimmune Diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_58","first-page":"2867","article-title":"Changes of Serum IL-6, IL-10 and TNF-\u03b1 Levels in Patients with Systemic Lupus Erythematosus and Their Clinical Value","volume":"13","author":"Jin","year":"2021","journal-title":"Am. J. Transl. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/art.22451","article-title":"Interleukin-6 and Chemokines in the Neuropsychiatric Manifestations of Systemic Lupus Erythematosus","volume":"56","author":"Llorente","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e1368","DOI":"10.1002\/iid3.1368","article-title":"Clinical Significance of Serum CXCL9, CXCL10, and CXCL11 in Patients with Lupus Nephritis","volume":"12","author":"Wang","year":"2024","journal-title":"Immun. Inflamm. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Kim, J.-W., Jung, J.-Y., Lee, S.-W., Baek, W.-Y., Kim, H.-A., and Suh, C.-H. (2022). S100A8 in Serum, Urine, and Saliva as a Potential Biomarker for Systemic Lupus Erythematosus. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.886209"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e3326","DOI":"10.1002\/jgm.3326","article-title":"Circulating miR-181a and miR-223 Expression with the Potential Value of Biomarkers for the Diagnosis of Systemic Lupus Erythematosus and Predicting Lupus Nephritis","volume":"23","author":"Rashad","year":"2021","journal-title":"J. Gene Med."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Greenan-Barrett, J., Doolan, G., Shah, D., Virdee, S., Robinson, G.A., Choida, V., Gak, N., de Gruijter, N., Rosser, E., and Al-Obaidi, M. (2021). Biomarkers Associated with Organ-Specific Involvement in Juvenile Systemic Lupus Erythematosus. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147619"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1177\/0961203318788167","article-title":"Composite Urinary Biomarkers to Predict Pathological Tubulointerstitial Lesions in Lupus Nephritis","volume":"27","author":"Ding","year":"2018","journal-title":"Lupus"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/rheumatology\/kep468","article-title":"Urinary Neutrophil Gelatinase-Associated Lipocalin as a Novel Biomarker for Disease Activity in Lupus Nephritis","volume":"49","author":"Rubinstein","year":"2010","journal-title":"Rheumatology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1177\/09612033211004727","article-title":"Clinico-Pathological Associations of Serum VCAM-1 and ICAM-1 Levels in Patients with Lupus Nephritis","volume":"30","author":"Yu","year":"2021","journal-title":"Lupus"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/0886022X.2020.1735416","article-title":"Clinicopathologic Characteristics and Outcomes of Lupus Nephritis with Positive Antineutrophil Cytoplasmic Antibody","volume":"42","author":"Wang","year":"2020","journal-title":"Ren. Fail."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"102463","DOI":"10.1016\/j.autrev.2020.102463","article-title":"A Review and Meta-Analysis of Anti-Ribosomal P Autoantibodies in Systemic Lupus Erythematosus","volume":"19","author":"Choi","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s12016-021-08865-2","article-title":"Autoantibodies in Neuropsychiatric Systemic Lupus Erythematosus (NPSLE): Can They Be Used as Biomarkers for the Differential Diagnosis of This Disease?","volume":"63","author":"Manca","year":"2022","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/art.23399","article-title":"Association of Cerebrospinal Fluid Anti-NR2 Glutamate Receptor Antibodies with Diffuse Neuropsychiatric Systemic Lupus Erythematosus","volume":"58","author":"Arinuma","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Fragoso-Loyo, H., Cabiedes, J., Orozco-Narv\u00e1ez, A., D\u00e1vila-Maldonado, L., Atisha-Fregoso, Y., Diamond, B., Llorente, L., and S\u00e1nchez-Guerrero, J. (2008). Serum and Cerebrospinal Fluid Autoantibodies in Patients with Neuropsychiatric Lupus Erythematosus. Implications for Diagnosis and Pathogenesis. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0003347"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13075-023-03146-z","article-title":"Novel CSF Biomarkers for Diagnosis and Integrated Analysis of Neuropsychiatric Systemic Lupus Erythematosus: Based on Antibody Profiling","volume":"25","author":"Ni","year":"2023","journal-title":"Arthritis Res. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Blachut, D., Przywara-Chowaniec, B., Tomasik, A., Kukulski, T., and Morawiec, B. (2023). Update of Potential Biomarkers in Risk Prediction and Monitoring of Atherosclerosis in Systemic Lupus Erythematosus to Prevent Cardiovascular Disease. Biomedicines, 11.","DOI":"10.3390\/biomedicines11102814"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/9\/4026\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:21:43Z","timestamp":1777551703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/9\/4026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":73,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["ijms27094026"],"URL":"https:\/\/doi.org\/10.3390\/ijms27094026","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]}}}